Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Now Who Needs a Painkiller? King and Pain Therapeutics Face a Remoxy Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

A filing is now expected in mid-2010, although the delay looks to be a bigger hit to Pain Therapeutics than King, S&P analyst says.

Related Content

Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance
Purdue Moves To Stave Off Branded, Generic Competitors To New OxyContin
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification
Acurox Drops Niacin, But King And Acura Need New Study For Reformulation
Acurox Approval Could Be Impossible Given Combination Drug Regs
King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?
Second Time Around: Joint Advisory Committee Will Review Purdue's OxyContin Again
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts